What is Global Follicle Stimulating Hormone Market?
The Global Follicle Stimulating Hormone Market is a sector that focuses on the production and distribution of Follicle Stimulating Hormone (FSH). FSH is a crucial hormone in the human body that plays a significant role in the reproductive system. It is responsible for the growth and maturation of ovarian follicles in women and the production of sperm in men. The market for this hormone is global, meaning it spans across different countries and continents. The demand for FSH is driven by various factors, including the increasing prevalence of infertility issues and the growing use of assisted reproductive technologies. However, the market also faces challenges such as stringent regulatory policies and high treatment costs. Despite these challenges, the market continues to grow, offering various opportunities for existing players and new entrants.
Recombinant FSH, Urinary FSH in the Global Follicle Stimulating Hormone Market:
The Global Follicle Stimulating Hormone Market is segmented into two main types: Recombinant FSH and Urinary FSH. Recombinant FSH is a type of FSH that is produced through genetic engineering. It is identical to the natural hormone and is used in the treatment of infertility. On the other hand, Urinary FSH is derived from the urine of postmenopausal women. It is used in fertility treatments to stimulate the development of multiple eggs for use in assisted reproductive technologies such as in-vitro fertilization. Both types of FSH have their advantages and disadvantages, and their usage depends on various factors such as the patient's condition, the doctor's preference, and the cost.
Infertility Treatment, Assisted Reproductive Technology in the Global Follicle Stimulating Hormone Market:
The Global Follicle Stimulating Hormone Market finds its application in various areas, including Infertility Treatment and Assisted Reproductive Technology. Infertility treatment involves the use of FSH to stimulate the ovaries to produce more eggs, increasing the chances of conception. Assisted Reproductive Technology (ART) refers to treatments and procedures that aim to achieve pregnancy by handling the eggs and sperm and manipulating their interaction. FSH is used in ART to stimulate the ovaries to produce multiple eggs, which are then used in procedures such as in-vitro fertilization and intracytoplasmic sperm injection. The use of FSH in these areas is driven by the increasing prevalence of infertility issues and the growing acceptance and use of ART.
Global Follicle Stimulating Hormone Market Outlook:
The market outlook for the Global Follicle Stimulating Hormone Market is positive. In 2022, the market was valued at US$ 1275.1 million. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.8% from 2023 to 2029, reaching a value of US$ 1550.6 million by 2029. This growth is driven by various factors, including the increasing prevalence of infertility issues, the growing use of assisted reproductive technologies, and the advancements in medical technology. However, the market also faces challenges such as stringent regulatory policies and high treatment costs. Despite these challenges, the market continues to grow, offering various opportunities for existing players and new entrants.
| Report Metric | Details |
| Report Name | Follicle Stimulating Hormone Market |
| Accounted market size in 2023 | US$ 1275.1 million |
| Forecasted market size in 2030 | US$ 1550.6 million |
| CAGR | 2.8% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Merck Serono, MSD, IBSA, Ferring, Livzon, Techwell, GenSci, Gedeon Richter, Teva |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
